• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy
AbstractThe aim of this study was to determine the effect of lncRNA HIF1A-AS2 on autophagy-associated drug resistance in small cell lung cancer (SCLC) cells. The expression of HIF1A-AS2 was silenced by siRNA in doxorubicin-sensitive H69 and doxorubicin-resistant H69AR cells. Then, cytotoxicity, apoptosis and autophagy analyses were carried out in the normoxic and CoCl2-induced hypoxic environment. The effect of HIF1A-AS2 on the expression levels of genes, which are associated with drug resistance and autophagy, was determinated by qRT-PCR analysis. The levels of MRP1, HIF-1 α and Beclin-1 were analyzed by western blot met...
Source: Medical Oncology - August 11, 2021 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 13, Pages 1187: Molecular Signature of Small Cell Lung Cancer after Treatment Failure: The MCM Complex as Therapeutic Target
In this study, we identified a gene expression signature of SCLC after treatment failure using SCLC clinical specimens (GEO accession number: GSE162102). A total of 1,136 genes were significantly upregulated in SCLC tissues. These upregulated genes were subjected to KEGG pathway analysis, and “cell cycle”, “Fanconi anemia”, “alcoholism”, “systemic lupus erythematosus”, “oocyte meiosis”, “homologous recombination”, “DNA replication”, and “p53 signaling” were identified as the enriched pathways among the genes. We focused on the cell cycle pathway and investigated the clinical significance of ...
Source: Cancers - March 10, 2021 Category: Cancer & Oncology Authors: Shunsuke Misono Keiko Mizuno Takayuki Suetsugu Kengo Tanigawa Nijiro Nohata Akifumi Uchida Hiroki Sanada Reona Okada Shogo Moriya Hiromasa Inoue Naohiko Seki Tags: Article Source Type: research

Friend leukemia virus integration 1 promotes tumorigenesis of small cell lung cancer cells by activating the miR-17-92 pathway.
This study uncovers FLI1 as an important driving factor that promotes tumor growth in SCLC through the miR-17-92 pathway. FLI1 may serve as an attractive target for therapeutic intervention of SCLC. PMID: 28410216 [PubMed - as supplied by publisher]
Source: Oncotarget - April 16, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Abstract A30: Characterizing the non-linear dependency of the CDK5-Rb axis in non-small cell lung cancer
In spite of recent therapeutics advances and early detection, lung cancer is still the leading cause of cancer-associated deaths worldwide. The five-year survival rates for its two major subtypes, small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are estimated to be 6% and 18%, respectively. This high mortality is due to its aggressive nature even when detected at an early stage. Besides its aggressive nature and tendency for early metastasis, another feature of lung cancer is the inactivation of the retinoblastoma protein (Rb) that is observed in both lung cancer subtypes. NSCLC exhibits Rb inactivation...
Source: Cancer Research - January 15, 2017 Category: Cancer & Oncology Authors: Jaileene Perez-Morales, Mauricio Cabrera-Rios, Jonathan Gonzalez-Flores, Pedro Santiago-Cardona Tags: Systems Biology Source Type: research

Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Authors: Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y, Park JH Abstract Maternal embryonic leucine zipper kinase (MELK), that plays a critical role in maintenance of cancer stem cells (CSCs), is predominantly expressed in various types of human cancer including small cell lung cancer (SCLC). SCLC usually acquires resistance to anti-cancer drugs and portends dismal prognosis. We have delineated roles of MELK in development/progression of SCLC and examined anti-tumor efficacy of OTS167, a highly potent MELK inhibitor, against SCLC. MELK expression was highly upregulated i...
Source: Oncotarget - February 13, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Evaluation of role of Notch3 signaling pathway in human lung cancer cells
Conclusion Notch3 signaling in lung carcinoma is dependent on cell type. In SCLC, Notch3 behaves as a tumor suppressor pathway, while in NSCLC it acts as a tumor-promoting pathway.
Source: Journal of Cancer Research and Clinical Oncology - February 2, 2016 Category: Cancer & Oncology Source Type: research

Expression of ADAM12 is regulated by E2F1 in small cell lung cancer.
Authors: Li Z, Wang Y, Kong L, Yue Z, Ma Y, Chen X Abstract Our previous study reported that ADAM12 was highly expressed in small cell lung cancer (SCLC) and could be an effective marker for diagnosis and prognosis. Yet, the reason for the high expression of ADAM12 in SCLC requires further elucidation. Transcription factor E2F1 has been receiving increasing attention due to the complexity and diversity of its function in cancer. In the present study, the expression of ADAM12 was significantly decreased following silencing of E2F1 expression by siRNA, thus indicating that E2F1 may regulate the expression of ADAM12 a...
Source: Oncology Reports - October 30, 2015 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Abstract 4954: Serine/arginine splicing factor 1 (SRSF1) mediates DNA repair and chemo-sensitivity and drives growth in small cell lung cancer
Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer. Despite a high response rate to chemotherapy, more than 95% of patients eventually die from SCLC. We have identified that Serine/Arginine Splicing Factor 1 (SRSF1) DNA copy number gain and mRNA over-expression in tumor is strongly associated with poor survival based on whole exome sequencing (WES) and transcriptomic sequencing of primary tumors from 99 Chinese SCLC patients. Here, SRSF1 is evaluated as a tumor driver in SCLC. Treatment of SCLC cell lines in vitro with a low dose of cisplatin or topotecan (two of the most common standard of care in...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Conley, S. J., Yao, X., Huang, J., Higgs, B., Hu, Z., Xiao, Z., Zhong, H., Liu, Z., Brohawn, P., Ge, X., Czapiga, M., Oganesyan, V., Fu, H., Tice, D., Herbst, R., Su, X., Gu, Y., Gu, J., Han, B., Richman, L., Jallal, B., Jiang, L., Shen, H., Yao, Y. Tags: Molecular and Cellular Biology Source Type: research

Abstract 1735: Identification of novel synthetic lethal interactions in small cell lung cancer with the proteasome inhibitor carfilzomib
Proteasome inhibition (PI) has emerged as a valuable cancer treatment in hematological malignancies by causing a disruption of protein homeostasis. While proteasome inhibitors have been historically unsuccessful in the clinic for solid tumors, all cancer cell lines succumb to proteasome inhibition in vitro. Solid tumor cell lines have a higher threshold for disruption of protein homeostasis; as they require continuous exposure to achieve cytotoxicity similar to pulsatile exposure of PI in heme cell lines. The in-vivo half-life of proteasome inhibitors is short (∼1hr) making it challenging to mimic in vitro continuous tre...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Masto, V. B., Lerner, A. G., Arastu-Kapur, S. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 3841: Effects of KEAP1 genetic and epigenetic silencing in SCLC cell lines
Conclusions. Our data provide new insights into the potential downstream effects of genetic and epigenetic Keap1/Nrf2 molecular deregulation in SCLCs, suggesting that the impairment of Keap1 activity actually induces the expression of cytoprotective enzymes also in small cell lung cancer cells. Validations on tissues from SCLC affected patients combined with in vitro pharmacological studies are demanded to establish new combined therapeutic strategies in targeted cancer treat-ments of this aggressive lung tumour histotype.Citation Format: Domenico Trombetta, Annamaria la Torre, Angelo Sparaneo, Teresa Balsamo, Massimiliano...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Trombetta, D., la Torre, A., Sparaneo, A., Balsamo, T., Copetti, M., Sanchez-Cespedes, M., Maiello, E., Graziano, P., Fazio, V. M., Muscarella, L. A. Tags: Molecular and Cellular Biology Source Type: research

Abstract 4: ABT-263 is effective in a subset of non-small cell lung cancer cell lines
Conclusion:We found that Calu3 and BID007 were sensitive to ABT-263. In the sensitive NSCLC cell lines, ABT-263 induces apoptosis irrespective of Mcl-1 expression levels.Citation Format: Aoi Kuroda, Keiko Ohgino, Hiroyuki Yasuda, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Tetsuo Tani, Shigenari Nukaga, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku. ABT-263 is effective in a subset of non-small cell lung cancer cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kuroda, A., Ohgino, K., Yasuda, H., Hamamoto, J., Arai, D., Ishioka, K., Tani, T., Nukaga, S., Kawada, I., Naoki, K., Soejima, K., Betsuyaku, T. Tags: Molecular and Cellular Biology Source Type: research

MTA1 downregulation inhibits malignant potential in a small cell lung cancer cell line.
Authors: Xue H, Wang H, Liu J, Liu H, Li C, Han L, Lin C, Zhan Q, Zhao Z, Qian H Abstract As a component of the nuclear remodeling and deacetylation complex (NuRD complex), metastasis-associated gene 1 (MTA1) has been reported to play a key role in cancer malignancy. However, whether MTA1 functions in small cell lung cancer (SCLC) malignant behavior and whether it is feasible to be used as a therapeutic target have not been evaluated. The present study aimed to investigate the effects of MTA1 downregulation on SCLC malignancy. First we demonstrated the overexpression of MTA1 in SCLC specimens. After knocking down ...
Source: Oncology Reports - December 18, 2014 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Role of SPHK1 Regulates Multi-drug Resistance of Small Cell Lung Cancer
and Its Clinical Significance
Background and objective Lung cancer is the leading cause of cancer-related deaths worldwide. Approximately 15% of all histological types consist of small cell lung cancer (SCLC). Chemotherapy is one of the major treatment method. Though the current first-line standard chemotherapy regimen for SCLC is active in most SCLC cases, however the disease recurs shortly after the first successful treatment with multi-drug resistance (MDR) phenotype. Our previously study showed that SPHK1 was associated with MDR in SCLC. The aim of this study is to investigate the role of sphingosine kinase 1 (SPHK1) showed in small cell lung multi...
Source: Chinese Journal of Lung Cancer - November 18, 2014 Category: Cancer & Oncology Source Type: research

Significance of c‐MET Overexpression in Cytotoxic Anticancer Drug Resistant Small Cell Lung Cancer Cells
In conclusion, increased c‐Met expression through an increase in the number of c‐MET gene loci is one of mechanisms of acquired resistance to the cytotoxic anticancer drugs. Our results add a new strategy that c‐MET is a target for overcoming the resistance to cytotoxic agents in SCLC. This article is protected by copyright. All rights reserved.
Source: Cancer Science - May 1, 2014 Category: Cancer & Oncology Authors: Hiroaki Ozasa, Tetsuya Oguri, Ken Maeno, Osamu Takakuwa, Eiji Kun, Yoshitaka Yagi, Takehiro Uemura, Daishi Kasai, Mikinori Miyazaki, Akio Niimi Tags: Original Article Source Type: research

Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype
Conclusions: E2F1 acts as a transcriptional activator for MMPs and directly enhances MMP transcription by binding to E2F1 binding sequences in the promoter, or indirectly activates MMPs through enhanced Sp1 and NF-kappa B as a consequence of E2F1 activation in SCLC.
Source: BMC Cancer - April 22, 2014 Category: Cancer & Oncology Authors: Zunling LiYanxia GuoHanming JiangTingguo ZhangChangzhu JinCharles YoungHuiqing Yuan Source Type: research

Pages: 1  2